Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-EGFR/c-MET/c-MET trispecific antibody GB263T

A Fc-enhanced trispecific antibody targeting epidermal growth factor receptor (EGFR) and two different epitopes of hepatocyte growth factor receptor (HGFR; c-Met), with potential antineoplastic activity. Upon administration, anti-EGFR/c-Met/c-met trispecific antibody GB263T simultaneously targets and binds to the extracellular domain of both EGFR and two different epitopes on c-Met expressed on tumor cells, thereby preventing receptor phosphorylation and inducing internalization of EGFR and c-Met. This downregulates the expression levels of both EGFR and c-Met proteins and prevents the activation of both EGFR- and c-Met-mediated signaling pathways. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.
Synonym:EGFR x cMET x cMET trispecific antibody GB263T
trispecific EGFR/cMET/cMET antibody GB263T
Code name:GB 263T
GB-263T
GB263T
Search NCI's Drug Dictionary